Long-term results of FK 506 eye drops following corneal transplantation;Langzeitergebnisse mit FK 506-augentropfen nach hornhaut-transplantation

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 1, 2008, Pages 57-61

  Reis, Alexander ^a   Mayweg, S ^b   Birnbaum, F ^a   Reinhard, T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cornea; Microbiology; Pharmacology

Indexed keywords

FLUOCORTOLONE; PREDNISOLONE ACETATE; TACROLIMUS;

ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNITY;

AGED; CHEMOTHERAPY, ADJUVANT; CORNEAL TRANSPLANTATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; TACROLIMUS; TREATMENT OUTCOME;

EID: 39149090692     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027133     Document Type: Article

References (15)

1. Alward WA. Duane's Opthalmology. Lippincott, 1996; Vol 3
2. Birnbaum F, Reis A, Bohringer D et al. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 2006; 81 (5): 767-772
3. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 25/357 (6380) nn): 695-697
4. Kawamura A, Teramura Y, Fujita Y et al. Blood and ocular tissue concentration of FK 506 in rabbits after single and repeated instillation of FK 506 ophthalmic suspension. Ltd. unpublished report CRD980048. Fujisawa Pharmaceutical Co
5. Kino T, Hatayama H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from Streptomyces: 1: Fermentation, isolation, and physio-chemical and biological characteristics. J Antibiot 1987; 40: 1249-1255
6. Pels L, Maas H, Tullo A. European Eye Bank Association Directory. Amsterdam: EEBA, 2000; Eighth edition
7. Reinhard T, Mayweg S, Reis A et al. Topical FK 506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. ranspl Int 2005; 18 (2): 193-197
8. Reinhard T, Reis A, Böhringer D et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years'results of a randomized prospective clinical trial. Graefe's Arch Clin Exp Ophthalmol 2001; 239 (5): 367-372
9. Reinhard T, Sundmacher R, Heering P. Systemic ciclosporin A in high risk keratoplasties. Graefe's Arch Clin Exp Ophthalmol 1996; 234: 115-121
10. Reis A, Reinhard T, Sundmacher R et al. A Comparative Investigation of the Effect of FK 506 (Prograf®) and Cyclosporin A (Sandimmun®, CSA) In Murine Corneal Transplantation. Graefe's Arch Clin Exp Ophthalmol 1998; 236: 785-789
11. Reis A, Reinhard T, Sundmacher R et al. FK506 and Mycophenolatemofetil: Two novel immunosuppressants in murine corneal transplantation. Transplant-Proc 1998; 30 (8): 4344-4347
12. Ruhlmann A, Nordheim A. Effects of the immunosuppressive drugs CsA and FK 506 on intracellular signalling and gene regulation. Immunobiology 1997; 198 (1-3): 192-206
13. Sawada S, Suzuki G, Kawase Y et al. Novel immunosuppressive agent, FK-506: In vitro effects on the cloned T cell activation. J Immunol 1987; 40: 1249-1255
14. Tanaka H, Kuroda A, Marusawa H et al. Physiochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19 (Suppl): 11-16
15. Yoshimura N, Matsui S, Hamashima T et al. Effects of a new immunosuppressive agent, FK-506, on human lymphocyte-responsiveness in vitro: 1:Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 1989; 47: 351-356